Combinatorial treatment of genistein and hypericin (Figure 4A) in human breast cancer cells resulted in the reduction of Bcl-2 expression while an increase in Bax expression suppressed Akt and ERK1/2 phosphorylation [57]. Here, BCL2 is linked to breast cancer.